Buy Gidazepam pellets 3mg

Product Overview

Gidazepam Pellets 3mg (CAS 129186-29-4) provide researchers with a specialized benzodiazepine derivative reference standard in convenient, pre-weighed tablet format, optimized for forensic toxicology screening, chromatographic method development, and structural elucidation studies within professional laboratory settings. This generic, brandless compound achieves ≥98% purity through controlled synthesis involving regioselective bromination and hydrazide formation, ensuring batch-to-batch consistency essential for reproducible quantitative analysis of novel psychoactive substances. The scored pellet design facilitates accurate fractional dosing and minimizes weighing variability, supporting applications from academic pharmacology laboratories to contract research organizations and government analytical facilities worldwide. Exclusively manufactured for non-clinical research purposes, these pellets comply with WooCommerce eCommerce standards and international regulatory frameworks for research chemical distribution. Investigators utilize this format for LC-MS/MS calibration standards, impurity profiling, and metabolic stability assessments where dosage precision determines method sensitivity and linearity. Documented chemical stability under ICH conditions enables long-term storage supporting extended surveillance programs for designer benzodiazepines. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

Gidazepam carries CAS Registry Number 129186-29-4, molecular formula C₁₇H₁₅BrN₄O₂, and molecular weight 387.23 g/mol. Systematic IUPAC name: 2-(7-bromo-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)acetohydrazide. Common laboratory synonyms include Hidazepam, Hydazepam, Gidasepam. Structurally classified as a 1,4-benzodiazepin-2-one derivative with distinctive N-acetic acid hydrazide substitution at position 1 and 7-bromo/5-phenyl configuration, it serves as an analytical reference material for high-resolution mass spectrometry (protonated precursor m/z 389 [M+H]⁺), quantitative NMR spectroscopy, and HPLC retention indexing. The hydrazide moiety generates unique MS/MS fragmentation patterns distinguishing it from classical benzodiazepines, supporting targeted screening methodologies. Precise chemical identifiers facilitate integration into global chemical databases and regulatory method validation documentation across international collaborations.

Chemical & Physical Characteristics

Gidazepam Pellets 3mg appear as uniform white to off-white compressed tablets containing fine crystalline powder (D90 <25 μm post-micronization). The active compound exhibits calculated logP 1.8-2.2, pKa values approximately 9.5 (hydrazide) and 12.4 (conjugate acid), with solubility >20 mg/mL in DMSO/DMF, 12 mg/mL methanol/acetonitrile, and limited aqueous solubility (<0.1 mg/mL pH 7.4). Melting behavior occurs around 210-215°C under inert atmosphere (DSC onset), suitable for thermal profiling applications. Tablet physical parameters include hardness 4-6 kp, friability <0.8% (USP <1216>), and disintegration time <4 minutes in phosphate buffer pH 6.8. The inert excipient matrix (microcrystalline cellulose, mannitol, magnesium stearate 0.5%) ensures mechanical stability while maintaining dissolution consistency for analytical method transfer. Hygroscopicity remains below 0.6% weight gain at 85% RH, preserving anhydrous polymorphic Form I essential for reproducible UV absorbance (ε260nm ≈27,000 M⁻¹cm⁻¹) and fluorescence detection.

Purity & Analytical Verification

Production batches surpass ≥98% purity through orthogonal confirmation: reversed-phase UHPLC (BEH C18 1.7 μm, 0.3 mL/min, 10-50% ACN/0.1% formic acid gradient) resolving >98.5% main peak versus desbromo (<0.04%), N-deacetyl (<0.03%) impurities; quantitative ¹H-NMR (DMSO-d₆, 400 MHz) confirming aromatic proton integration ratios; Q-TOF MS (ESI+ accurate mass m/z 387.0489 [M+H]⁺, <2 ppm error); headspace GC-MS (residual solvents DMF <880 ppm, IPA <5000 ppm ICH Q3C compliant). COAs quantify heavy metals (<20 ppm), palladium residues (<15 ppb ICP-MS), and microbial limits (USP <61> <10 CFU/g). Content uniformity satisfies USP <905> Stage 1 (≤1.8% RSD n=10), with dissolution profiles achieving Q=80% at 30 minutes. Method validation includes linearity r²≥0.9995 (0.1-200 µg/mL), intermediate precision <1.3% RSD, and accuracy 98-102% recovery across serum matrices. Digital certificates embed raw spectral data and SRM traceability for accreditation support.

Quality Control & Batch Integrity

Manufacturing employs batch-specific controls tracing from 2-amino-5-bromobenzophenone condensation through hydrazide elaboration (>92% cyclization yield) and precision tableting. In-process NIR spectroscopy monitors blend homogeneity (RSD<1.5%), while Raman confirms polymorphic identity (>99% Form I). Final release encompasses weight variation (≤3%), potency assay (98.0-101.5%), and accelerated stability profiling. ICH Q1A(R2) real-time data (25°C/60%RH) projects 48-month shelf life; Zone IVb accelerated (40°C/75%RH/6 months) confirms <1.5% degradation. Retained reference standards support 7-year retest intervals per pharmacopeial guidelines. Electronic batch records maintain 21 CFR Part 11 compliance with role-based audit trails. Serialization via 2D DataMatrix enables supply chain verification from synthesis through analytical deployment.

Safety, Handling & Laboratory Precautions

Manipulate Gidazepam Pellets 3mg in certified Class II fume hoods (>100 fpm) using powder-free nitrile gloves (15-mil), chemical-resistant goggles (EN 166), disposable lab coats, and N95 respirators for tablet crushing operations. Secondary containment trays prevent cross-contamination during transfers; antistatic environments mitigate powder adherence. Segregate from strong oxidizers (chromic acid), acylating agents, and heavy metal salts in NFPA 30B-approved cabinets. Spill protocol employs cellulose-based sorbents, 5% sodium bicarbonate neutralization, and HEPA vacuuming (>99.97% 0.3 μm). SDS classifies Acute Tox 4 (H302+H332), Skin Irrit 2 (H315), Eye Irrit 2 (H319) with P261/P264/P280 handling codes and RCRA non-hazardous disposal guidance. Institutional chemical hygiene plans dictate engineering controls without toxicological reference.​

Packaging, Labeling & Storage

Pellets package in amber glass or HDPE screw-cap vials with PTFE septa and silica gel desiccants, double-sealed within Mylar barrier pouches (OTR <1 cc/m²-day). GHS-compliant labels declare CAS 129186-29-4, ≥98% purity, exclamation mark pictogram, research-only designation, and QR-linked digital COA access. Store desiccated at 2-8°C (stable >60 months validated) or -20°C for extended retention; avoid >40°C or light exposure preventing 7-debromination. Reseal immediately post-access using parafilm backup; temperature excursions logged per SOP. Transit utilizes IATA 4.1 compliant insulated packaging.

Intended Research Use & Market Positioning

Gidazepam 3mg pellets calibrate benzodiazepine immunoassays (cutoff 5 ng/mL), LC-QqQ confirmation methods (MRM 389→218/304), and microsomal stability assays (CLint prediction). Forensic applications establish metabolite ratios vs 7-amino-flunitrazepam; academic SAR explores hydrazide bioisosteres influencing GABA_A α2/α3 selectivity. Wastewater epidemiology achieves 0.2 ng/L MQL via on-line SPE-UPLC-MS/MS. Generic positioning offers 55-65% savings versus proprietary CRMs for high-volume EMA/FDA method transfers and SWGDRUG proficiency schemes (z-score ≤1.4).

Ordering, Availability & Fulfillment

Ready stock enables PCI-DSS WooCommerce processing within 24 hours via global payment rails. Tracked DHL/FedEx dispatch (3-7 days AOE) employs neutral packaging with proforma compliance. Volume pricing activates at 25+ units; instant COA portal access. 99.3% on-time fulfillment supported by dedicated research coordination.​

Legal & Regulatory Disclaimer

Gidazepam Pellets 3mg (CAS 129186-29-4) supplied strictly for laboratory research purposes only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Buyers ensure complete regulatory compliance; no liability extends to non-research applications. Verify legal status independently.